Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155724 | 0.90 | MAOB (0.44) | MAOBMAOADAO | |
| SCHEMBL28399599 | 0.89 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL13338101 | 0.86 | MAOB (0.59) | MAOBMAOAGSTP1CA12CA1 | |
| SCHEMBL28398922 | 0.85 | MAOB (0.66) | MAOBMAOA | |
| SCHEMBL5252207 | 0.81 | DAO (0.50) | MAOBMAOADAO | |
| SCHEMBL3256254 | 0.81 | MAOB (0.44) | MAOBMAOADAO | |
| SCHEMBL28393172 | 0.80 | MAOB (0.65) | MAOBMAOA | |
| SCHEMBL1477458 | 0.79 | GSTP1 (0.44) | MAOBMAOAGSTP1CA12CA1 | |
| SCHEMBL5415271 | 0.78 | MAP4K4 (0.45) | MAOBMAOA | |
| SCHEMBL28560284 | 0.78 | NPC1 (0.45) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3636636-B1 | PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE | MITSUI CHEMICALS AGRO INC (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-107344940-B | BTK inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| CN-109336829-A | Aryl methanamide compounds of the triazole structure containing 1,2,3- and application thereof | 沈阳药科大学 | 2019-02-15 | — | — | CN | disclosed |
| US-10174026-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-12-04 | — | — | US | disclosed |
| EP-2968282-B1 | HISTONE DEMENTHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873697-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2731436-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8609653-B2 | Azaindole compounds and methods for treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2013012649-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012649-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| US-4867915-A | LIPOXYGENASE INHIBITORS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1989-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | MAOB 588/4885MAOA 537/4885GSTP1 1721/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | MAOB 1261/4885MAOA 1625/4885GSTP1 2277/4885 |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | AZI2, TPMT, INMT | MAOB 334/4885MAOA 316/4885GSTP1 4136/4885 |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | MAOB 588/4885MAOA 537/4885GSTP1 1721/4885 |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | BTK, BCL9, LCK | MAOB 1675/4885MAOA 3393/4885GSTP1 1728/4885 |
| US-10174026-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | MAOB 588/4885MAOA 537/4885GSTP1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.